Imatinib Unknown Status Phase 3 Trials for Gastrointestinal Stromal Tumors Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00685828Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor
NCT00812240A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment